International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 3 , Pages 897-903 , 1 March 2009

The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin; AZD2171) Inhibits Endothelial Cell Function and Growth of Human Renal Tumor Xenografts

  • Dietmar W. Siemann, Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Florida, Gainesville, FL
    • Corresponding Author InformationReprint requests to: Dietmar W. Siemann, Ph.D., Department of Radiation Oncology, University of Florida, 2000 S.W. Archer Road, Gainesville, FL 32610. Tel: (352) 265-0287; Fax: (352) 265-0759
    • ,
  • W.D. Brazelle, Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Florida, Gainesville, FL
    • ,
  • Juliane M. Jürgensmeier, Ph.D.

      Affiliations

    • Cancer Bioscience, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom

Received 30 June 2008 ,Revised 3 September 2008 ,Accepted 20 October 2008.

References 

  1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15–18
  2. Hendrix MJ, Seftor EA, Hess AR, et al. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer. 2003;3:411–421
  3. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351:250–259
  4. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–660
  5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676
  6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364
  7. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl. 1):2–10
  8. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027
  9. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000;27:115–123
  10. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–1095
  11. Yoshino S, Kato M, Okada K. Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res. 2000;20:591–594
  12. Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol. 2000;163:343–347
  13. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35:133–137
  14. Harris AL. Antiangiogenesis for cancer therapy. Lancet. 1997;349(Suppl. 2):SII13–SII15
  15. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis. 2000;21:505–515
  16. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–3508
  17. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  18. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389–4400
  19. Smith KA, Hill SA, Begg AC, et al. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer. 1988;57:247–253
  20. Curtis ACS. Area and volume measurements by random sampling methods. Med Biol Illustra. 1960;10:261–266
  21. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24–40
  22. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  23. Elaraj DM, White DE, Steinberg SM, et al. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother. 2004;27:259–264
  24. Rini BI, Halabi S, Taylor J, et al. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004;10:2584–2586
  25. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505–2512
  26. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045–3054
  27. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res. 2007;13(Suppl.):S4617–S4622
  28. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007;25:445–451
  29. van Herpen C, Drevs J, van Cruijsen H, et al. Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies. [Abstract] Proc Am Soc Clin Oncol. 2007;25:3560
  30. Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. [Abstract] Proc Am Soc Clin Oncol. 2007;5:5093
  31. Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer. 2007;97:65–72
  32. Smith NR, James NH, Oakley I, et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther. 2007;6:2198–2208
  33. Williams KJ, Telfer BA, Shannon AM, et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit. Mol Cancer Ther. 2007;6:599–606
  34. Horsman MR, Siemann DW. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66:11520–11539

 Supported in part by a grant from AstraZeneca and US Public Health Service Grant CA089655 from the U.S. National Cancer Institute.

 Conflict of interest: These studies were supported in part by a research grant to Dr. Siemann from AstraZeneca. Dr. Juliane Jürgensmeier is an employee of AstraZeneca.

PII: S0360-3016(08)03673-0

doi: 10.1016/j.ijrobp.2008.10.031

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 3 , Pages 897-903 , 1 March 2009

Article Tools

* Image Usage & Resolution